Comparison of effects of bare metal versus drug-eluting stent implantation on biomarker levels following percutaneous coronary intervention for non-ST-elevation acute coronary syndrome.

[1]  Y. Jang,et al.  Comparison of effects of drug-eluting stents versus bare metal stents on plasma C-reactive protein levels. , 2005, The American journal of cardiology.

[2]  S. Petersen,et al.  Troponin Elevation After Percutaneous Coronary Intervention Directly Represents the Extent of Irreversible Myocardial Injury: Insights From Cardiovascular Magnetic Resonance Imaging , 2005, Circulation.

[3]  E. Alegrı́a,et al.  Platelet aggregation inhibition blocks C-reactive protein and interleukin-6 (IL-6) elevation after the coronary angioplasty: effect of the -174 G/C IL-6 gene polymorphism. , 2004, The American journal of cardiology.

[4]  V. Pasceri,et al.  Randomized Trial of Atorvastatin for Reduction of Myocardial Damage During Coronary Intervention: Results From the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) Study , 2004, Circulation.

[5]  D. Yellon,et al.  Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. , 2003, Journal of the American College of Cardiology.

[6]  M. Bennett,et al.  IN-STENT STENOSIS: PATHOLOGY AND IMPLICATIONS FOR THE DEVELOPMENT OF DRUG ELUTING STENTS , 2003, Heart.

[7]  F. Crea,et al.  Immunosuppressive Therapy for the Prevention of Restenosis after Coronary Artery Stent Implantation (IMPRESS Study). , 2002, Journal of the American College of Cardiology.

[8]  A. Gaspardone,et al.  Effect of atorvastatin (80 mg) initiated at the time of coronary artery stent implantation on C-reactive protein and six-month clinical events. , 2002, The American journal of cardiology.

[9]  V. Hasselblad,et al.  Prognostic significance of elevated troponin I after percutaneous coronary intervention. , 2002, Journal of the American College of Cardiology.

[10]  L. Deckelbaum,et al.  Abciximab Suppresses the Rise in Levels of Circulating Inflammatory Markers After Percutaneous Coronary Revascularization , 2001, Circulation.

[11]  C M Gibson,et al.  Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. , 2000, Circulation.

[12]  E. Braunwald,et al.  Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Thrombolysis In Myocardial Infarction (TIMI) Study Group. , 1999, Circulation.

[13]  D Wybenga,et al.  Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. , 1996, The New England journal of medicine.

[14]  E. Braunwald,et al.  TIMI frame count: a quantitative method of assessing coronary artery flow. , 1996, Circulation.

[15]  T Sandor,et al.  Quantitative angiographic and statistical methods to assess serial changes in coronary luminal diameter and implications for atherosclerosis regression trials. , 1992, The American journal of cardiology.

[16]  W. Ganz,et al.  The thrombolysis in myocardial infarction (TIMI) trial. , 1985, The New England journal of medicine.

[17]  F. Fedele,et al.  Early elevation of interleukin-1beta and interleukin-6 levels after bare or drug-eluting stent implantation in patients with stable angina. , 2006, Thrombosis research.

[18]  Harry,et al.  C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. , 1993, Blood.

[19]  H. S. Mueller,et al.  The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. , 1985, The New England journal of medicine.